EmTech: Risks of Gene-Editing Drugs Need Study, Pioneer Warns

September 25, 2014

(MIT Technology Review) – Citing the risk of deadly mistakes, a leading researcher speaking at MIT Technology Review’s EmTech conference on Tuesday said the risks of gene editing need to be better understood before the technology can be used in medical studies.Feng Zhang, a researcher at MIT, helped invent a powerful new way to alter DNA that he compared in his talk to a “search-and-replace function for the genome.” Several startups have already sprung up to turn the technology into new kinds of gene-therapy drugs, including CRISPR Therapeutics and Editas Medicine, a biotechnology company that Zhang cofounded last year with venture capitalists who invested $43 million.